{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:47:09Z","timestamp":1794120429280,"version":"4.8.0"},"reference-count":312,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41584-019-0186-x","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T09:07:58Z","timestamp":1551776878000},"page":"257-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":255,"title":["Inclusion body myositis: clinical features and pathogenesis"],"prefix":"10.1038","volume":"15","author":[{"given":"Steven A.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"186_CR1","first-page":"533","volume":"12","author":"H Unverricht","year":"1887","unstructured":"Unverricht, H. Polymyositis acuta progressiva. Z. Klin. Med. 12, 533\u2013549 (1887).","journal-title":"Z. Klin. Med."},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0738-081X(88)90044-2","volume":"6","author":"A Bohan","year":"1988","unstructured":"Bohan, A. History and classification of polymyositis and dermatomyositis. Clin. Dermatol. 6, 3\u20138 (1988).","journal-title":"Clin. Dermatol."},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0029-1206170","volume":"17","author":"H Uverricht","year":"1891","unstructured":"Uverricht, H. Dermatomyositis acuta. Dtsch. Med. Wochenschr. 17, 41\u201344 (1891).","journal-title":"Dtsch. Med. Wochenschr."},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archneur.60.5.780","volume":"60","author":"TD Levine","year":"2003","unstructured":"Levine, T. D. History of dermatomyositis. Arch. Neurol. 60, 780\u2013782 (2003).","journal-title":"Arch. Neurol."},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/WNL.28.1.8","volume":"28","author":"S Carpenter","year":"1978","unstructured":"Carpenter, S., Karpati, G., Heller, I. & Eisen, A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 28, 8\u201317 (1978).","journal-title":"Neurology"},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1212\/WNL.41.6.936","volume":"41","author":"AM Emslie-Smith","year":"1991","unstructured":"Emslie-Smith, A. M. & Engel, A. G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 41, 936\u2013939 (1991).","journal-title":"Neurology"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","volume":"61","author":"MF Meulen van der","year":"2003","unstructured":"van der Meulen, M. F. et al. Polymyositis: an overdiagnosed entity. Neurology 61, 316\u2013321 (2003).","journal-title":"Neurology"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2015.02.014","volume":"25","author":"J Vlekkert van de","year":"2015","unstructured":"van de Vlekkert, J., Hoogendijk, J. E. & de Visser, M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul. Disord. 25, 451\u2013456 (2015).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas, M. C. Inflammatory muscle diseases. N. Engl. J. Med. 372, 1734\u20131747 (2015).","journal-title":"N. Engl. J. Med."},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft, P. W. & Fiorentino, D. F. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr. Rheumatol. Rep. 20, 28 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1586\/1744666X.2013.842467","volume":"9","author":"J Schmidt","year":"2013","unstructured":"Schmidt, J. & Dalakas, M. C. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev. Clin. Immunol. 9, 1125\u20131133 (2013).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11926-014-0477-9","volume":"16","author":"PM Machado","year":"2014","unstructured":"Machado, P. M. et al. Ongoing developments in sporadic inclusion body myositis. Curr. Rheumatol. Rep. 16, 477 (2014).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","volume":"32","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie, M. M. & Barohn, R. J. Inclusion body myositis. Neurol. Clin. 32, 629\u2013646 (2014).","journal-title":"Neurol. Clin."},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2014.09.012","volume":"22","author":"FL Mastaglia","year":"2015","unstructured":"Mastaglia, F. L. & Needham, M. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J. Clin. Neurosci. 22, 6\u201313 (2015).","journal-title":"J. Clin. Neurosci."},{"key":"186_CR16","first-page":"1871","volume":"22","author":"SA Greenberg","year":"2016","unstructured":"Greenberg, S. A. Inclusion body myositis. Continuum 22, 1871\u20131888 (2016).","journal-title":"Continuum"},{"key":"186_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.neurol.2016.07.016","volume":"172","author":"L Gallay","year":"2016","unstructured":"Gallay, L. & Petiot, P. Sporadic inclusion-body myositis: recent advances and the state of the art in 2016. Rev. Neurol. 172, 581\u2013586 (2016).","journal-title":"Rev. Neurol."},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.clinph.2015.12.011","volume":"127","author":"M Needham","year":"2016","unstructured":"Needham, M. & Mastaglia, F. L. Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment. Clin. Neurophysiol. 127, 1764\u20131773 (2016).","journal-title":"Clin. Neurophysiol."},{"key":"186_CR19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/BOR.0000000000000436","volume":"29","author":"K Schmidt","year":"2017","unstructured":"Schmidt, K. & Schmidt, J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr. Opin. Rheumatol. 29, 632\u2013638 (2017).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00401-015-1384-5","volume":"129","author":"O Benveniste","year":"2015","unstructured":"Benveniste, O. et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 129, 611\u2013624 (2015).","journal-title":"Acta Neuropathol."},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/acn3.419","volume":"4","author":"CW Keller","year":"2017","unstructured":"Keller, C. W., Schmidt, J. & Lunemann, J. D. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann. Clin. Transl Neurol. 4, 422\u2013445 (2017).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1126\/science.158.3807.1453","volume":"158","author":"SM Chou","year":"1967","unstructured":"Chou, S. M. Myxovirus-like structures in a case of human chronic polymyositis. Science 158, 1453\u20131455 (1967).","journal-title":"Science"},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ana.410250309","volume":"25","author":"H Nishino","year":"1989","unstructured":"Nishino, H., Engel, A. G. & Rima, B. K. Inclusion body myositis: the mumps virus hypothesis. Ann. Neurol. 25, 260\u2013264 (1989).","journal-title":"Ann. Neurol."},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0046-8177(91)90057-V","volume":"22","author":"M Kallajoki","year":"1991","unstructured":"Kallajoki, M. et al. Inclusion body myositis and paramyxoviruses. Hum. Pathol. 22, 29\u201332 (1991).","journal-title":"Hum. Pathol."},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/(SICI)1097-4598(199601)19:1<23::AID-MUS4>3.0.CO;2-A","volume":"19","author":"SA Fox","year":"1996","unstructured":"Fox, S. A., Ward, B. K., Robbins, P. D., Mastaglia, F. L. & Swanson, N. R. Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction. Muscle Nerve 19, 23\u201328 (1996).","journal-title":"Muscle Nerve"},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","volume":"86","author":"A Uruha","year":"2016","unstructured":"Uruha, A. et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology 86, 211\u2013217 (2016).","journal-title":"Neurology"},{"key":"186_CR27","first-page":"240","volume":"25","author":"EJ Yunis","year":"1971","unstructured":"Yunis, E. J. & Samaha, F. J. Inclusion body myositis. Lab. Invest. 25, 240\u2013248 (1971).","journal-title":"Lab. Invest."},{"key":"186_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/archneur.1982.00510240022006","volume":"39","author":"MJ Danon","year":"1982","unstructured":"Danon, M. J., Reyes, M. G., Perurena, O. H., Masdeu, J. C. & Manaligod, J. R. Inclusion body myositis. A corticosteroid-resistant idiopathic inflammatory myopathy. Arch. Neurol. 39, 760\u2013764 (1982).","journal-title":"Arch. Neurol."},{"key":"186_CR29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1212\/WNL.33.9.1109","volume":"33","author":"A Eisen","year":"1983","unstructured":"Eisen, A., Berry, K. & Gibson, G. Inclusion body myositis (IBM): myopathy or neuropathy? Neurology 33, 1109\u20131114 (1983).","journal-title":"Neurology"},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/archneur.1987.00520230042011","volume":"44","author":"SP Ringel","year":"1987","unstructured":"Ringel, S. P., Kenny, C. E., Neville, H. E., Giorno, R. & Carry, M. R. Spectrum of inclusion body myositis. Arch. Neurol. 44, 1154\u20131157 (1987).","journal-title":"Arch. Neurol."},{"key":"186_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/art.1780300406","volume":"30","author":"LH Calabrese","year":"1987","unstructured":"Calabrese, L. H., Mitsumoto, H. & Chou, S. M. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum. 30, 397\u2013403 (1987).","journal-title":"Arthritis Rheum."},{"key":"186_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/112.3.727","volume":"112","author":"BP Lotz","year":"1989","unstructured":"Lotz, B. P., Engel, A. G., Nishino, H., Stevens, J. C. & Litchy, W. J. Inclusion body myositis. Observations in 40 patients. Brain 112, 727\u2013747 (1989).","journal-title":"Brain"},{"key":"186_CR33","first-page":"1385","volume":"19","author":"ME Sayers","year":"1992","unstructured":"Sayers, M. E., Chou, S. M. & Calabrese, L. H. Inclusion body myositis: analysis of 32 cases. J. Rheumatol. 19, 1385\u20131389 (1992).","journal-title":"J. Rheumatol."},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0404.1994.tb01647.x","volume":"89","author":"C Lindberg","year":"1994","unstructured":"Lindberg, C., Persson, L. I., Bjorkander, J. & Oldfors, A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol. Scand. 89, 123\u2013131 (1994).","journal-title":"Acta Neurol. Scand."},{"key":"186_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ana.410400407","volume":"40","author":"AA Amato","year":"1996","unstructured":"Amato, A. A. et al. Inclusion body myositis: clinical and pathological boundaries. Ann. Neurol. 40, 581\u2013586 (1996).","journal-title":"Ann. Neurol."},{"key":"186_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/(SICI)1097-4598(199805)21:5<659::AID-MUS17>3.0.CO;2-Q","volume":"21","author":"KJ Felice","year":"1998","unstructured":"Felice, K. J., Relva, G. M. & Conway, S. R. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 21, 659\u2013661 (1998).","journal-title":"Muscle Nerve"},{"key":"186_CR37","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/mus.1178","volume":"24","author":"BA Phillips","year":"2001","unstructured":"Phillips, B. A. et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve 24, 1526\u20131534 (2001).","journal-title":"Muscle Nerve"},{"key":"186_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","volume":"252","author":"UA Badrising","year":"2005","unstructured":"Badrising, U. A. et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J. Neurol. 252, 1448\u20131454 (2005).","journal-title":"J. Neurol."},{"key":"186_CR39","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","volume":"134","author":"O Benveniste","year":"2011","unstructured":"Benveniste, O. et al. Long-term observational study of sporadic inclusion body myositis. Brain 134, 3176\u20133184 (2011).","journal-title":"Brain"},{"key":"186_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3233\/JND-150138","volume":"3","author":"MA Price","year":"2016","unstructured":"Price, M. A. et al. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. J. Neuromuscul. Dis. 3, 67\u201375 (2016).","journal-title":"J. Neuromuscul. Dis."},{"key":"186_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/00005792-200109000-00006","volume":"80","author":"KJ Felice","year":"2001","unstructured":"Felice, K. J. & North, W. A. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 80, 320\u2013327 (2001).","journal-title":"Medicine"},{"key":"186_CR42","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2007.138891","volume":"79","author":"M Needham","year":"2008","unstructured":"Needham, M. et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J. Neurol. Neurosurg. Psychiatry 79, 1056\u20131060 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"186_CR43","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1093\/brain\/awr217","volume":"134","author":"FM Cox","year":"2011","unstructured":"Cox, F. M. et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 134, 3167\u20133175 (2011).","journal-title":"Brain"},{"key":"186_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","volume":"23","author":"A Cortese","year":"2013","unstructured":"Cortese, A. et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul. Disord. 23, 404\u2013412 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.nmd.2014.04.009","volume":"24","author":"JY Hogrel","year":"2014","unstructured":"Hogrel, J. Y. et al. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials. Neuromuscul. Disord. 24, 604\u2013610 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mus.25373","volume":"55","author":"LN Alfano","year":"2016","unstructured":"Alfano, L. N. et al. Modeling functional decline over time in sporadic inclusion body myositis. Muscle Nerve 55, 526\u2013531 (2016).","journal-title":"Muscle Nerve"},{"key":"186_CR47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1212\/WNL.57.3.548","volume":"57","author":"MR Rose","year":"2001","unstructured":"Rose, M. R. et al. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 57, 548\u2013550 (2001).","journal-title":"Neurology"},{"key":"186_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","volume":"16","author":"K Arahata","year":"1984","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16, 193\u2013208 (1984).","journal-title":"Ann. Neurol."},{"key":"186_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ana.410160207","volume":"16","author":"AG Engel","year":"1984","unstructured":"Engel, A. G. & Arahata, K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann. Neurol. 16, 209\u2013215 (1984).","journal-title":"Ann. Neurol."},{"key":"186_CR50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ana.410190203","volume":"19","author":"K Arahata","year":"1986","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann. Neurol. 19, 112\u2013125 (1986).","journal-title":"Ann. Neurol."},{"key":"186_CR51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.410230210","volume":"23","author":"K Arahata","year":"1988","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann. Neurol. 23, 168\u2013173 (1988).","journal-title":"Ann. Neurol."},{"key":"186_CR52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/jaut.1994.1023","volume":"7","author":"TP O\u2019Hanlon","year":"1994","unstructured":"O\u2019Hanlon, T. P., Dalakas, M. C., Plotz, P. H. & Miller, F. W. The \u03b1\u03b2T cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J. Autoimmun. 7, 321\u2013333 (1994).","journal-title":"J. Autoimmun."},{"key":"186_CR53","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/eji.1830241114","volume":"24","author":"C Lindberg","year":"1994","unstructured":"Lindberg, C., Oldfors, A. & Tarkowski, A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur. J. Immunol. 24, 2659\u20132663 (1994).","journal-title":"Eur. J. Immunol."},{"key":"186_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-3083.1995.tb03587.x","volume":"41","author":"C Lindberg","year":"1995","unstructured":"Lindberg, C., Oldfors, A. & Tarkowski, A. Local T cell proliferation and differentiation in inflammatory myopathies. Scand. J. Immunol. 41, 421\u2013426 (1995).","journal-title":"Scand. J. Immunol."},{"key":"186_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1365-3083.1996.d01-10.x","volume":"43","author":"IM Fyhr","year":"1996","unstructured":"Fyhr, I. M., Moslemi, A. R., Tarkowski, A., Lindberg, C. & Oldfors, A. Limited T cell receptor V gene usage in inclusion body myositis. Scand. J. Immunol. 43, 109\u2013114 (1996).","journal-title":"Scand. J. Immunol."},{"key":"186_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0165-5728(97)00122-7","volume":"79","author":"IM Fyhr","year":"1997","unstructured":"Fyhr, I. M. et al. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J. Neuroimmunol. 79, 185\u2013189 (1997).","journal-title":"J. Neuroimmunol."},{"key":"186_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0165-5728(97)00246-4","volume":"84","author":"A Bender","year":"1998","unstructured":"Bender, A., Behrens, L., Engel, A. G. & Hohlfeld, R. T cell heterogeneity in muscle lesions of inclusion body myositis. J. Neuroimmunol. 84, 86\u201391 (1998).","journal-title":"J. Neuroimmunol."},{"key":"186_CR58","first-page":"2030","volume":"123","author":"K Amemiya","year":"2000","unstructured":"Amemiya, K., Granger, R. P. & Dalakas, M. C. Clonal restriction of T cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123, 2030\u20132039 (2000).","journal-title":"Studies in repeated muscle biopsies. Brain"},{"key":"186_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-3083.2003.01251.x","volume":"58","author":"K Muntzing","year":"2003","unstructured":"Muntzing, K., Lindberg, C., Moslemi, A. R. & Oldfors, A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand. J. Immunol. 58, 195\u2013200 (2003).","journal-title":"Scand. J. Immunol."},{"key":"186_CR60","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/brain\/awl020","volume":"129","author":"D Dimitri","year":"2006","unstructured":"Dimitri, D. et al. Shared blood and muscle CD8+T cell expansions in inclusion body myositis. Brain 129, 986\u2013995 (2006).","journal-title":"Brain"},{"key":"186_CR61","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1212\/01.wnl.0000265398.77681.09","volume":"69","author":"M Salajegheh","year":"2007","unstructured":"Salajegheh, M. et al. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69, 1672\u20131679 (2007).","journal-title":"Neurology"},{"key":"186_CR62","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1002\/art.27665","volume":"62","author":"JM Pandya","year":"2010","unstructured":"Pandya, J. M. et al. Expanded T cell receptor V\u03b2-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum. 62, 3457\u20133466 (2010).","journal-title":"Arthritis Rheum."},{"key":"186_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088788","volume":"9","author":"Y Allenbach","year":"2014","unstructured":"Allenbach, Y. et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLOS ONE 9, e88788 (2014).","journal-title":"PLOS ONE"},{"key":"186_CR64","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/brain\/aww024","volume":"139","author":"SA Greenberg","year":"2016","unstructured":"Greenberg, S. A., Pinkus, J. L., Amato, A. A., Kristensen, T. & Dorfman, D. M. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 139, 1348\u20131360 (2016).","journal-title":"Brain"},{"key":"186_CR65","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/aww053","volume":"139","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld, R. & Schulze-Koops, H. Cytotoxic T cells go awry in inclusion body myositis. Brain 139, 1312\u20131314 (2016).","journal-title":"Brain"},{"key":"186_CR66","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","volume":"61","author":"C Lindberg","year":"2003","unstructured":"Lindberg, C., Trysberg, E., Tarkowski, A. & Oldfors, A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61, 260\u2013262 (2003).","journal-title":"Neurology"},{"key":"186_CR67","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas, M. C. et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132, 1536\u20131544 (2009).","journal-title":"Brain"},{"key":"186_CR68","doi-asserted-by":"publisher","first-page":"5L","DOI":"10.1002\/acr.22992","volume":"69","author":"JY Hogrel","year":"2017","unstructured":"Hogrel, J. Y. et al. Rapamycin vs. placebo for the treatment of inclusion body myositis: improvement of the 6\u202fmin walking distance, a functional scale, the FVC and muscle quantitative MRI. Arthritis Rheumatol. 69, 5L (2017).","journal-title":"Arthritis Rheumatol."},{"key":"186_CR69","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11926-008-0053-2","volume":"10","author":"IN Targoff","year":"2008","unstructured":"Targoff, I. N. Autoantibodies and their significance in myositis. Curr. Rheumatol. Rep. 10, 333\u2013340 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR70","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai, M. & Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881\u2013888 (1980).","journal-title":"Arthritis Rheum."},{"key":"186_CR71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","volume":"5","author":"M Reichlin","year":"1976","unstructured":"Reichlin, M. & Mattioli, M. Description of a serological reaction characteristic of polymyositis. Clin. Immunol. Immunopathol. 5, 12\u201320 (1976).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"186_CR72","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290\u2013302 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"186_CR73","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","volume":"59","author":"SA Greenberg","year":"2002","unstructured":"Greenberg, S. A. et al. Molecular profiles of inflammatory myopathies. Neurology 59, 1170\u20131182 (2002).","journal-title":"Neurology"},{"key":"186_CR74","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","volume":"65","author":"SA Greenberg","year":"2005","unstructured":"Greenberg, S. A. et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65, 1782\u20131787 (2005).","journal-title":"Neurology"},{"key":"186_CR75","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4049\/jimmunol.178.1.547","volume":"178","author":"EM Bradshaw","year":"2007","unstructured":"Bradshaw, E. M. et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J. Immunol. 178, 547\u2013556 (2007).","journal-title":"J. Immunol."},{"key":"186_CR76","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/mus.21739","volume":"42","author":"M Salajegheh","year":"2010","unstructured":"Salajegheh, M. et al. Permissive environment for B cell maturation in myositis muscle in the absence of B cell follicles. Muscle Nerve 42, 576\u2013583 (2010).","journal-title":"Muscle Nerve"},{"key":"186_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046709","volume":"7","author":"A Ray","year":"2012","unstructured":"Ray, A. et al. Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLOS ONE 7, e46709 (2012).","journal-title":"PLOS ONE"},{"key":"186_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020266","volume":"6","author":"M Salajegheh","year":"2011","unstructured":"Salajegheh, M., Lam, T. & Greenberg, S. A. Autoantibodies against a 43kDa muscle protein in inclusion body myositis. PLOS ONE 6, e20266 (2011).","journal-title":"PLOS ONE"},{"key":"186_CR79","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.23840","volume":"73","author":"HB Larman","year":"2013","unstructured":"Larman, H. B. et al. Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73, 408\u2013418 (2013).","journal-title":"Ann. Neurol."},{"key":"186_CR80","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23822","volume":"73","author":"H Pluk","year":"2013","unstructured":"Pluk, H. et al. Autoantibodies to cytosolic 5\u2032-nucleotidase IA in inclusion body myositis. Ann. Neurol. 73, 397\u2013407 (2013).","journal-title":"Ann. Neurol."},{"key":"186_CR81","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","volume":"48","author":"JR Mendell","year":"1991","unstructured":"Mendell, J. R., Sahenk, Z., Gales, T. & Paul, L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch. Neurol. 48, 1229\u20131234 (1991).","journal-title":"Arch. Neurol."},{"key":"186_CR82","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/116.2.325","volume":"116","author":"A Oldfors","year":"1993","unstructured":"Oldfors, A., Larsson, N. G., Lindberg, C. & Holme, E. Mitochondrial DNA deletions in inclusion body myositis. Brain 116, 325\u2013336 (1993).","journal-title":"Brain"},{"key":"186_CR83","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/brain\/awn053","volume":"131","author":"J Schmidt","year":"2008","unstructured":"Schmidt, J. et al. Interrelation of inflammation and APP in sIBM: IL-1\u03b2 induces accumulation of \u03b2-amyloid in skeletal muscle. Brain 131, 1228\u20131240 (2008).","journal-title":"Brain"},{"key":"186_CR84","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ajpath.2013.06.003","volume":"183","author":"M Freret","year":"2013","unstructured":"Freret, M. et al. Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. Am. J. Pathol. 183, 893\u2013904 (2013).","journal-title":"Am. J. Pathol."},{"key":"186_CR85","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/nan.12149","volume":"41","author":"KA Rygiel","year":"2015","unstructured":"Rygiel, K. A. et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol. Appl. Neurobiol. 41, 288\u2013303 (2015).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"186_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2249.1994.tb06604.x","volume":"98","author":"MJ Garlepp","year":"1994","unstructured":"Garlepp, M. J., Laing, B., Zilko, P. J., Ollier, W. & Mastaglia, F. L. HLA associations with inclusion body myositis. Clin. Exp. Immunol. 98, 40\u201345 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"186_CR87","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0165-5728(97)00245-2","volume":"84","author":"BM Koffman","year":"1998","unstructured":"Koffman, B. M., Sivakumar, K., Simonis, T., Stroncek, D. & Dalakas, M. C. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J. Neuroimmunol. 84, 139\u2013142 (1998).","journal-title":"J. Neuroimmunol."},{"key":"186_CR88","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00415-003-0204-3","volume":"250","author":"JB Lampe","year":"2003","unstructured":"Lampe, J. B. et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J. Neurol. 250, 1313\u20131317 (2003).","journal-title":"J. Neurol."},{"key":"186_CR89","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1399-0039.2004.00310.x","volume":"64","author":"P Price","year":"2004","unstructured":"Price, P. et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens 64, 575\u2013580 (2004).","journal-title":"Tissue Antigens"},{"key":"186_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.nmd.2006.02.002","volume":"16","author":"AP Scott","year":"2006","unstructured":"Scott, A. P. et al. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1. Neuromuscul. Disord. 16, 311\u2013315 (2006).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.clineuro.2011.03.016","volume":"113","author":"A Rojana-udomsart","year":"2011","unstructured":"Rojana-udomsart, A. et al. The association of sporadic inclusion body myositis and Sj\u00f6gren\u2019s syndrome in carriers of HLA-DR3 and the 8.1\u2005MHC ancestral haplotype. Clin. Neurol. Neurosurg. 113, 559\u2013563 (2011).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"186_CR92","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jneuroim.2012.05.003","volume":"250","author":"A Rojana-udomsart","year":"2012","unstructured":"Rojana-udomsart, A. et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J. Neuroimmunol. 250, 77\u201382 (2012).","journal-title":"J. Neuroimmunol."},{"key":"186_CR93","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jneuroim.2012.09.003","volume":"254","author":"A Rojana-udomsart","year":"2013","unstructured":"Rojana-udomsart, A. et al. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC class II region in sporadic inclusion body myositis. J. Neuroimmunol. 254, 174\u2013177 (2013).","journal-title":"J. Neuroimmunol."},{"key":"186_CR94","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/art.40045","volume":"69","author":"S Rothwell","year":"2017","unstructured":"Rothwell, S. et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 69, 1090\u20131099 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"186_CR95","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas, M. C. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48, 712\u2013716 (1997).","journal-title":"Neurology"},{"key":"186_CR96","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mus.20584","volume":"34","author":"SA Greenberg","year":"2006","unstructured":"Greenberg, S. A., Pinkus, J. L. & Amato, A. A. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 34, 406\u2013416 (2006).","journal-title":"Muscle Nerve"},{"key":"186_CR97","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","volume":"70","author":"N Chahin","year":"2008","unstructured":"Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418\u2013424 (2008).","journal-title":"Neurology"},{"key":"186_CR98","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.24919","volume":"81","author":"N Tawara","year":"2017","unstructured":"Tawara, N. et al. Pathomechanisms of anti-cytosolic 5\u2032-nucleotidase 1\u2009A autoantibodies in sporadic inclusion body myositis. Ann. Neurol. 81, 512\u2013525 (2017).","journal-title":"Ann. Neurol."},{"key":"186_CR99","unstructured":"Johns Hopkins University. Myopathy, myofibrillar, 1; MFM1. OMIM https:\/\/www.omim.org\/entry\/601419 (2014)."},{"key":"186_CR100","doi-asserted-by":"publisher","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","volume":"8","author":"M Ahmed","year":"2016","unstructured":"Ahmed, M. et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci. Transl Med. 8, 331ra41 (2016).","journal-title":"Sci. Transl Med."},{"key":"186_CR101","first-page":"653","volume":"120","author":"K Sivakumar","year":"1997","unstructured":"Sivakumar, K., Semino-Mora, C. & Dalakas, M. C. An\u00a0inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 120, 653\u2013661 (1997).","journal-title":"Studies in three families. Brain"},{"key":"186_CR102","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/ard.2004.025494","volume":"64","author":"B Ranque-Francois","year":"2005","unstructured":"Ranque-Francois, B. et al. Familial inflammatory inclusion body myositis. Ann. Rheum. Dis. 64, 634\u2013637 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"186_CR103","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2169\/internalmedicine.42.1035","volume":"42","author":"M Tateyama","year":"2003","unstructured":"Tateyama, M. et al. Familial inclusion body myositis: a report on two Japanese sisters. Intern. Med. 42, 1035\u20131038 (2003).","journal-title":"Intern. Med."},{"key":"186_CR104","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JND-160198","volume":"4","author":"A Callan","year":"2017","unstructured":"Callan, A., Capkun, G., Vasanthaprasad, V., Freitas, R. & Needham, M. A. Systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis. J. Neuromuscul. Dis. 4, 127\u2013137 (2017).","journal-title":"J. Neuromuscul. Dis."},{"key":"186_CR105","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","volume":"16","author":"JA Tan","year":"2013","unstructured":"Tan, J. A. et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int. J. Rheum. Dis. 16, 331\u2013338 (2013).","journal-title":"Int. J. Rheum. Dis."},{"key":"186_CR106","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","volume":"55","author":"UA Badrising","year":"2000","unstructured":"Badrising, U. A. et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55, 1385\u20131387 (2000).","journal-title":"Neurology"},{"key":"186_CR107","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1212\/WNL.0000000000003504","volume":"88","author":"S Lefter","year":"2017","unstructured":"Lefter, S., Hardiman, O. & Ryan, A. M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 88, 304\u2013313 (2017).","journal-title":"Neurology"},{"key":"186_CR108","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s00415-011-6185-8","volume":"259","author":"N Suzuki","year":"2012","unstructured":"Suzuki, N. et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J. Neurol. 259, 554\u2013556 (2012).","journal-title":"J. Neurol."},{"key":"186_CR109","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ene.12627","volume":"22","author":"GC Dobloug","year":"2015","unstructured":"Dobloug, G. C. et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur. J. Neurol. 22, 672 (2015).","journal-title":"Eur. J. Neurol."},{"key":"186_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0524-x","volume":"11","author":"N Suzuki","year":"2016","unstructured":"Suzuki, N. et al. Multicenter questionnaire survey for sporadic inclusion body myositis in Japan. Orphanet J. Rare Dis. 11, 146 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"186_CR111","first-page":"445","volume":"35","author":"FC Wilson","year":"2008","unstructured":"Wilson, F. C., Ytterberg, S. R., St Sauver, J. L. & Reed, A. M. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J. Rheumatol. 35, 445\u2013447 (2008).","journal-title":"J. Rheumatol."},{"key":"186_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-015-0647-z","volume":"9","author":"A Chilingaryan","year":"2015","unstructured":"Chilingaryan, A., Rison, R. A. & Beydoun, S. R. Misdiagnosis of inclusion body myositis: two case reports and a retrospective chart review. J. Med. Case Rep. 9, 169 (2015).","journal-title":"J. Med. Case Rep."},{"key":"186_CR113","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mus.24562","volume":"52","author":"AD Paltiel","year":"2015","unstructured":"Paltiel, A. D. et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve 52, 527\u2013533 (2015).","journal-title":"Muscle Nerve"},{"key":"186_CR114","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1080\/03007995.2018.1486294","volume":"34","author":"A Keshishian","year":"2018","unstructured":"Keshishian, A., Greenberg, S. A., Agashivala, N., Baser, O. & Johnson, K. Health care costs and comorbidities for patients with inclusion body myositis. Curr. Med. Res. Opin. 34, 1679\u20131685 (2018).","journal-title":"Curr. Med. Res. Opin."},{"key":"186_CR115","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/0003489414525588","volume":"123","author":"EH Ko","year":"2014","unstructured":"Ko, E. H. & Rubin, A. D. Dysphagia due to inclusion body myositis: case presentation and review of the literature. Ann. Otol. Rhinol. Laryngol. 123, 605\u2013608 (2014).","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"186_CR116","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","volume":"256","author":"FM Cox","year":"2009","unstructured":"Cox, F. M. et al. Detecting dysphagia in inclusion body myositis. J. Neurol. 256, 2009\u20132013 (2009).","journal-title":"J. Neurol."},{"key":"186_CR117","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/00005537-199807000-00009","volume":"108","author":"SM Houser","year":"1998","unstructured":"Houser, S. M., Calabrese, L. H. & Strome, M. Dysphagia in patients with inclusion body myositis. Laryngoscope 108, 1001\u20131005 (1998).","journal-title":"Laryngoscope"},{"key":"186_CR118","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","volume":"87","author":"TH Oh","year":"2008","unstructured":"Oh, T. H., Brumfield, K. A., Hoskin, T. L., Kasperbauer, J. L. & Basford, J. R. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am. J. Phys. Med. Rehabil. 87, 883\u2013889 (2008).","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"186_CR119","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1212\/WNL.43.6.1241","volume":"43","author":"DS Riminton","year":"1993","unstructured":"Riminton, D. S., Chambers, S. T., Parkin, P. J., Pollock, M. & Donaldson, I. M. Inclusion body myositis presenting solely as dysphagia. Neurology 43, 1241\u20131243 (1993).","journal-title":"Neurology"},{"key":"186_CR120","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mus.880140514","volume":"14","author":"A Verma","year":"1991","unstructured":"Verma, A., Bradley, W. G., Adesina, A. M., Sofferman, R. & Pendlebury, W. W. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 14, 470\u2013473 (1991).","journal-title":"Muscle Nerve"},{"key":"186_CR121","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.nmd.2014.08.003","volume":"24","author":"PM Rodriguez Cruz","year":"2014","unstructured":"Rodriguez Cruz, P. M., Needham, M., Hollingsworth, P., Mastaglia, F. L. & Hillman, D. R. Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscul. Disord. 24, 1036\u20131041 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR122","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","volume":"84","author":"S Brady","year":"2013","unstructured":"Brady, S., Squier, W. & Hilton-Jones, D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J. Neurol. Neurosurg. Psychiatry 84, 1240\u20131246 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"186_CR123","first-page":"1897","volume":"29","author":"E Dion","year":"2002","unstructured":"Dion, E. et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J. Rheumatol. 29, 1897\u20131906 (2002).","journal-title":"J. Rheumatol."},{"key":"186_CR124","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","volume":"50","author":"FM Cox","year":"2011","unstructured":"Cox, F. M. et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology 50, 1153\u20131161 (2011).","journal-title":"Rheumatology"},{"key":"186_CR125","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1017\/cjn.2014.35","volume":"41","author":"Y Inaishi","year":"2014","unstructured":"Inaishi, Y. et al. MRI for evaluation of flexor digitorum profundus muscle involvement in inclusion body myositis. Can. J. Neurol. Sci. 41, 780\u2013781 (2014).","journal-title":"Can. J. Neurol. Sci."},{"key":"186_CR126","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/mus.24661","volume":"52","author":"G Tasca","year":"2015","unstructured":"Tasca, G. et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 52, 956\u2013962 (2015).","journal-title":"Muscle Nerve"},{"key":"186_CR127","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2214\/AJR.17.17849","volume":"209","author":"JB Guimaraes","year":"2017","unstructured":"Guimaraes, J. B. et al. Sporadic inclusion body myositis: MRI findings and correlation with clinical and functional parameters. AJR Am. J. Roentgenol. 209, 1340\u20131347 (2017).","journal-title":"AJR Am. J. Roentgenol."},{"key":"186_CR128","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/qjmed\/hcy065","volume":"111","author":"K Tsukita","year":"2018","unstructured":"Tsukita, K., Yagita, K., Sakamaki-Tsukita, H. & Suenaga, T. Sporadic inclusion body myositis: magnetic resonance imaging and ultrasound characteristics. QJM 111, 667\u2013668 (2018).","journal-title":"QJM"},{"key":"186_CR129","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/mus.24056","volume":"49","author":"Y Noto","year":"2014","unstructured":"Noto, Y. et al. Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris: a diagnostic ultrasound pattern in sporadic inclusion body myositis. Muscle Nerve 49, 745\u2013748 (2014).","journal-title":"Muscle Nerve"},{"key":"186_CR130","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ene.12899","volume":"23","author":"H Nodera","year":"2016","unstructured":"Nodera, H. et al. Intramuscular dissociation of echogenicity in the triceps surae characterizes sporadic inclusion body myositis. Eur. J. Neurol. 23, 588\u2013596 (2016).","journal-title":"Eur. J. Neurol."},{"key":"186_CR131","first-page":"996","volume":"36","author":"J Albayda","year":"2018","unstructured":"Albayda, J. et al. Pattern of muscle involvement in inclusion body myositis: a sonographic study. Clin. Exp. Rheumatol. 36, 996\u20131002 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"186_CR132","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ultrasmedbio.2018.03.026","volume":"44","author":"D Bachasson","year":"2018","unstructured":"Bachasson, D., Dubois, G. J. R., Allenbach, Y., Benveniste, O. & Hogrel, J. Y. Muscle shear wave elastography in inclusion body myositis: feasibility, reliability and relationships with muscle impairments. Ultrasound Med. Biol. 44, 1423\u20131432 (2018).","journal-title":"Ultrasound Med. Biol."},{"key":"186_CR133","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/WNL.0000000000003337","volume":"87","author":"A Olthoff","year":"2016","unstructured":"Olthoff, A. et al. Evaluation of dysphagia by novel real-time MRI. Neurology 87, 2132\u20132138 (2016).","journal-title":"Neurology"},{"key":"186_CR134","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<115::AID-MUS15>3.0.CO;2-2","volume":"21","author":"BM Koffman","year":"1998","unstructured":"Koffman, B. M., Rugiero, M. & Dalakas, M. C. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21, 115\u2013117 (1998).","journal-title":"Muscle Nerve"},{"key":"186_CR135","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/mus.24199","volume":"50","author":"SA Greenberg","year":"2014","unstructured":"Greenberg, S. A. Cytoplasmic 5\u2032-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 50, 488\u2013492 (2014).","journal-title":"Muscle Nerve"},{"key":"186_CR136","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","volume":"87","author":"NA Goyal","year":"2016","unstructured":"Goyal, N. A. et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J. Neurol. Neurosurg. Psychiatry 87, 373\u2013378 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"186_CR137","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/acr.22600","volume":"68","author":"TE Lloyd","year":"2016","unstructured":"Lloyd, T. E. et al. Cytosolic 5\u2032-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res. 68, 66\u201371 (2016).","journal-title":"Arthritis Care Res."},{"key":"186_CR138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13317-016-0088-8","volume":"7","author":"SL Kramp","year":"2016","unstructured":"Kramp, S. L. et al. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis. Auto Immun. Highlights 7, 16 (2016).","journal-title":"Auto Immun. Highlights"},{"key":"186_CR139","first-page":"600","volume":"28","author":"KJ Felice","year":"2018","unstructured":"Felice, K. J. et al. Sensitivity and clinical utility of the anti-cytosolic 5\u2019-nucleotidase 1\u2009A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center. Neuromuscul. Disord. 28, 600\u2013664 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR140","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","volume":"75","author":"MK Herbert","year":"2016","unstructured":"Herbert, M. K. et al. Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 75, 696\u2013701 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"186_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2017.07.002","volume":"472","author":"Y Muro","year":"2017","unstructured":"Muro, Y., Nakanishi, H., Katsuno, M., Kono, M. & Akiyama, M. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts. Clin. Chim. Acta 472, 1\u20134 (2017).","journal-title":"Clin. Chim. Acta"},{"key":"186_CR142","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3389\/fimmu.2018.01200","volume":"9","author":"A Rietveld","year":"2018","unstructured":"Rietveld, A. et al. Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus. Front. Immunol. 9, 1200 (2018).","journal-title":"Front. Immunol."},{"key":"186_CR143","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2990.1990.tb01267.x","volume":"16","author":"C Mhiri","year":"1990","unstructured":"Mhiri, C. & Gherardi, R. Inclusion body myositis in French patients. A clinicopathological evaluation. Neuropathol. Appl. Neurobiol. 16, 333\u2013344 (1990).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"186_CR144","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/jemt.20186","volume":"67","author":"V Askanas","year":"2005","unstructured":"Askanas, V. & Engel, W. K. Molecular pathology and pathogenesis of inclusion-body myositis. Microsc. Res. Tech. 67, 114\u2013120 (2005).","journal-title":"Microsc. Res. Tech."},{"key":"186_CR145","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","volume":"24","author":"PM Rodriguez Cruz","year":"2014","unstructured":"Rodriguez Cruz, P. M. et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul. Disord. 24, 1025\u20131035 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR146","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1212\/WNL.0000000000004333","volume":"89","author":"C Ikenaga","year":"2017","unstructured":"Ikenaga, C. et al. Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology 89, 1060\u20131068 (2017).","journal-title":"Neurology"},{"key":"186_CR147","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jns.2008.11.010","volume":"278","author":"P Temiz","year":"2009","unstructured":"Temiz, P., Weihl, C. C. & Pestronk, A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J. Neurol. Sci. 278, 25\u201329 (2009).","journal-title":"J. Neurol. Sci."},{"key":"186_CR148","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","volume":"23","author":"A Pestronk","year":"2011","unstructured":"Pestronk, A. Acquired immune and inflammatory myopathies: pathologic classification. Curr. Opin. Rheumatol. 23, 595\u2013604 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR149","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0960-8966(00)00219-4","volume":"11","author":"MF Meulen van der","year":"2001","unstructured":"van der Meulen, M. F. et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul. Disord. 11, 447\u2013451 (2001).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR150","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487\u20131498 (1991).","journal-title":"N. Engl. J. Med."},{"key":"186_CR151","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","volume":"28","author":"FL Mastaglia","year":"2002","unstructured":"Mastaglia, F. L. & Phillips, B. A. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum. Dis. Clin. North Am. 28, 723\u2013741 (2002).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"186_CR152","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/00002281-200211000-00004","volume":"14","author":"R Tawil","year":"2002","unstructured":"Tawil, R. & Griggs, R. C. Inclusion body myositis. Curr. Opin. Rheumatol. 14, 653\u2013657 (2002).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR153","unstructured":"Verschuuren, J. J., van Engelen, B. G. M., van der Hoeven, H. & Hoogendijk, J. Inclusion body myositis diagnostic criteria. Inclusion Body Myositis. http:\/\/ibmmyositis.com\/emery81.pdf (1997)."},{"key":"186_CR154","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs, R. C. et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705\u2013713 (1995).","journal-title":"Ann. Neurol."},{"key":"186_CR155","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","volume":"20","author":"D Hilton-Jones","year":"2010","unstructured":"Hilton-Jones, D. et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord. 20, 142\u2013147 (2010).","journal-title":"Neuromuscul Disord."},{"key":"186_CR156","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","volume":"20","author":"O Benveniste","year":"2010","unstructured":"Benveniste, O. & Hilton-Jones, D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul. Disord. 20, 414\u2013421 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR157","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose, M. R. 188th ENMC International Workshop: Inclusion Body Myositis, 2\u20134 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044\u20131055 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR158","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd, T. E. et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83, 426\u2013433 (2014).","journal-title":"Neurology"},{"key":"186_CR159","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/rheumatology\/41.4.440","volume":"41","author":"P Kanellopoulos","year":"2002","unstructured":"Kanellopoulos, P., Baltoyiannis, C. & Tzioufas, A. G. Primary Sj\u00f6gren\u2019s syndrome associated with inclusion body myositis. Rheumatology 41, 440\u2013444 (2002).","journal-title":"Rheumatology"},{"key":"186_CR160","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00296-012-2556-4","volume":"33","author":"M Misterska-Skora","year":"2013","unstructured":"Misterska-Skora, M., Sebastian, A., Dziegiel, P., Sebastian, M. & Wiland, P. Inclusion body myositis associated with Sj\u00f6gren\u2019s syndrome. Rheumatol. Int. 33, 3083\u20133086 (2013).","journal-title":"Rheumatol. Int."},{"key":"186_CR161","first-page":"457","volume":"33","author":"S Colafrancesco","year":"2015","unstructured":"Colafrancesco, S. et al. Myositis in primary Sj\u00f6gren\u2019s syndrome: data from a multicentre cohort. Clin. Exp. Rheumatol. 33, 457\u2013464 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"186_CR162","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","volume":"88","author":"TE Lloyd","year":"2017","unstructured":"Lloyd, T. E. et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 88, 1454\u20131460 (2017).","journal-title":"Neurology"},{"key":"186_CR163","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jnen\/nlv023","volume":"75","author":"A Hiniker","year":"2016","unstructured":"Hiniker, A., Daniels, B. H. & Margeta, M. T-cell-mediated inflammatory myopathies in HIV-positive individuals: a histologic study of 19 cases. J. Neuropathol. Exp. Neurol. 75, 239\u2013245 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"186_CR164","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/brain\/119.6.1887","volume":"119","author":"EJ Cupler","year":"1996","unstructured":"Cupler, E. J. et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 119, 1887\u20131893 (1996).","journal-title":"Brain"},{"key":"186_CR165","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.nmd.2018.01.005","volume":"28","author":"P Couture","year":"2018","unstructured":"Couture, P. et al. Inclusion body myositis and human immunodeficiency virus type 1: a new case report and literature review. Neuromuscul. Disord. 28, 334\u2013338 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR166","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/nen.0b013e31815f38b7","volume":"67","author":"E Matsuura","year":"2008","unstructured":"Matsuura, E. et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J. Neuropathol. Exp. Neurol. 67, 41\u201349 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"186_CR167","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00415-009-5350-9","volume":"257","author":"FM Cox","year":"2010","unstructured":"Cox, F. M. et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J. Neurol. 257, 447\u2013451 (2010).","journal-title":"J. Neurol."},{"key":"186_CR168","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1756-185X.2010.01470.x","volume":"13","author":"VS Limaye","year":"2010","unstructured":"Limaye, V. S., Lester, S., Blumbergs, P. & Roberts-Thomson, P. J. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int. J. Rheum. Dis. 13, 132\u2013137 (2010).","journal-title":"Int. J. Rheum. Dis."},{"key":"186_CR169","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjd.12245","volume":"168","author":"YT Lai","year":"2013","unstructured":"Lai, Y. T. et al. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow-up study. Br. J. Dermatol. 168, 1054\u20131059 (2013).","journal-title":"Br. J. Dermatol."},{"key":"186_CR170","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1468-3083.2011.04437.x","volume":"27","author":"H Wang","year":"2013","unstructured":"Wang, H., Tang, J., Chen, X., Li, F. & Luo, J. Lipid profiles in untreated patients with dermatomyositis. J. Eur. Acad. Dermatol. Venereol. 27, 175\u2013179 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"186_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089827","volume":"9","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. Altered lipid levels in untreated patients with early polymyositis. PLOS ONE 9, e89827 (2014).","journal-title":"PLOS ONE"},{"key":"186_CR172","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/acr.22520","volume":"67","author":"LP Diederichsen","year":"2015","unstructured":"Diederichsen, L. P. et al. Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study. Arthritis Care Res. 67, 848\u2013854 (2015).","journal-title":"Arthritis Care Res."},{"key":"186_CR173","first-page":"461","volume":"55","author":"SK Rai","year":"2016","unstructured":"Rai, S. K., Choi, H. K., Sayre, E. C. & Avina-Zubieta, J. A. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology 55, 461\u2013469 (2016).","journal-title":"Rheumatology"},{"key":"186_CR174","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/ncprheum0092","volume":"2","author":"Y Sherer","year":"2006","unstructured":"Sherer, Y. & Shoenfeld, Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2, 99\u2013106 (2006).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"186_CR175","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2015.05.024","volume":"161","author":"J Ahearn","year":"2015","unstructured":"Ahearn, J., Shields, K. J., Liu, C. C. & Manzi, S. Cardiovascular disease biomarkers across autoimmune diseases. Clin. Immunol. 161, 59\u201363 (2015).","journal-title":"Clin. Immunol."},{"key":"186_CR176","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11926-012-0248-4","volume":"14","author":"H Alexanderson","year":"2012","unstructured":"Alexanderson, H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr. Rheumatol. Rep. 14, 244\u2013251 (2012).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR177","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/16501970306110","volume":"35","author":"S Arnardottir","year":"2003","unstructured":"Arnardottir, S., Alexanderson, H., Lundberg, I. E. & Borg, K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J. Rehabil. Med. 35, 31\u201335 (2003).","journal-title":"J. Rehabil. Med."},{"key":"186_CR178","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CND.0b013e3181237291","volume":"8","author":"LG Johnson","year":"2007","unstructured":"Johnson, L. G., Edwards, D. J., Walters, S. E., Thickbroom, G. W. & Mastaglia, F. L. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J. Clin. Neuromuscul. Dis. 8, 187\u2013194 (2007).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"186_CR179","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mus.21230","volume":"39","author":"KC Parker","year":"2009","unstructured":"Parker, K. C. et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 39, 739\u2013753 (2009).","journal-title":"Muscle Nerve"},{"key":"186_CR180","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/WNL.58.2.326","volume":"58","author":"P Cherin","year":"2002","unstructured":"Cherin, P. et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58, 326 (2002).","journal-title":"Neurology"},{"key":"186_CR181","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mus.23895","volume":"48","author":"K Pars","year":"2013","unstructured":"Pars, K. et al. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 48, 838\u2013839 (2013).","journal-title":"Muscle Nerve"},{"key":"186_CR182","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000441490","volume":"7","author":"P Cherin","year":"2015","unstructured":"Cherin, P., Delain, J. C., de Jaeger, C. & Crave, J. C. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep. Neurol. 7, 227\u2013232 (2015).","journal-title":"Case Rep. Neurol."},{"key":"186_CR183","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol. Ther. 25, 870\u2013879 (2017).","journal-title":"Mol. Ther."},{"key":"186_CR184","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/j.ymthe.2017.09.002","volume":"25","author":"SA Greenberg","year":"2017","unstructured":"Greenberg, S. A. Unfounded claims of improved functional outcomes attributed to follistatin gene therapy in inclusion body myositis. Mol. Ther. 25, 2235\u20132237 (2017).","journal-title":"Mol. Ther."},{"key":"186_CR185","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter, M. C. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22\u201328 (2000).","journal-title":"J. Neurol."},{"key":"186_CR186","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas, M. C. et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56, 323\u2013327 (2001).","journal-title":"Neurology"},{"key":"186_CR187","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ana.10121","volume":"51","author":"UA Badrising","year":"2002","unstructured":"Badrising, U. A. et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann. Neurol. 51, 369\u2013372 (2002).","journal-title":"Ann. Neurol."},{"key":"186_CR188","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","volume":"57","author":"G Muscle Study","year":"2001","unstructured":"Muscle Study, G. Randomized pilot trial of \u03b2INF1a (Avonex) in patients with inclusion body myositis. Neurology 57, 1566\u20131570 (2001).","journal-title":"Neurology"},{"key":"186_CR189","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","volume":"63","author":"G Muscle Study","year":"2004","unstructured":"Muscle Study, G. Randomized pilot trial of high-dose \u03b2INF-1a in patients with inclusion body myositis. Neurology 63, 718\u2013720 (2004).","journal-title":"Neurology"},{"key":"186_CR190","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","volume":"58","author":"SB Rutkove","year":"2002","unstructured":"Rutkove, S. B. et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 58, 1081\u20131087 (2002).","journal-title":"Neurology"},{"key":"186_CR191","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato, A. A. et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83, 2239\u20132246 (2014).","journal-title":"Neurology"},{"key":"186_CR192","first-page":"4367","volume":"68","author":"AA Amato","year":"2016","unstructured":"Amato, A. A. et al. A randomized, double-blind, placebo-controlled study of bimagrumab in patients with sporadic inclusion body myositis [abstract 8L]. Arthritis Rheumatol. 68, 4367\u20134369 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"186_CR193","first-page":"649","volume":"86","author":"SM Chou","year":"1968","unstructured":"Chou, S. M. Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch. Pathol. 86, 649\u2013658 (1968).","journal-title":"Arch. Pathol."},{"key":"186_CR194","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ana.410370107","volume":"37","author":"Z Rifai","year":"1995","unstructured":"Rifai, Z., Welle, S., Kamp, C. & Thornton, C. A. Ragged red fibers in normal aging and inflammatory myopathy. Ann. Neurol. 37, 24\u201329 (1995).","journal-title":"Ann. Neurol."},{"key":"186_CR195","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1212\/01.wnl.0000192127.63013.8d","volume":"66","author":"A Oldfors","year":"2006","unstructured":"Oldfors, A. et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 66, S49\u2013S55 (2006).","journal-title":"Neurology"},{"key":"186_CR196","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0304-3940(91)90230-Q","volume":"130","author":"V Askanas","year":"1991","unstructured":"Askanas, V., Serdaroglu, P., Engel, W. K. & Alvarez, R. B. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci. Lett. 130, 73\u201376 (1991).","journal-title":"Neurosci. Lett."},{"key":"186_CR197","first-page":"31","volume":"141","author":"V Askanas","year":"1992","unstructured":"Askanas, V., Engel, W. K. & Alvarez, R. B. Light and electron microscopic localization of \u03b2-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am. J. Pathol. 141, 31\u201336 (1992).","journal-title":"Am. J. Pathol."},{"key":"186_CR198","first-page":"177","volume":"144","author":"V Askanas","year":"1994","unstructured":"Askanas, V., Engel, W. K., Bilak, M., Alvarez, R. B. & Selkoe, D. J. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am. J. Pathol. 144, 177\u2013187 (1994).","journal-title":"Am. J. Pathol."},{"key":"186_CR199","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11926-010-0102-5","volume":"12","author":"SA Greenberg","year":"2010","unstructured":"Greenberg, S. A. Theories of the pathogenesis of inclusion body myositis. Curr. Rheumatol. Rep. 12, 221\u2013228 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR200","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/00002281-200311000-00009","volume":"15","author":"V Askanas","year":"2003","unstructured":"Askanas, V. & Engel, W. K. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-\u03b2, misfolded proteins, predisposing genes, and aging. Curr. Opin. Rheumatol. 15, 737\u2013744 (2003).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR201","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1212\/01.wnl.0000192128.13875.1e","volume":"66","author":"V Askanas","year":"2006","unstructured":"Askanas, V. & Engel, W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with A\u03b2, protein misfolding, and proteasome inhibition. Neurology 66, S39\u2013S48 (2006).","journal-title":"Neurology"},{"key":"186_CR202","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.bbadis.2014.09.005","volume":"1852","author":"V Askanas","year":"2015","unstructured":"Askanas, V., Engel, W. K. & Nogalska, A. Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim. Biophys. Acta 1852, 633\u2013643 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"186_CR203","doi-asserted-by":"publisher","first-page":"b2680","DOI":"10.1136\/bmj.b2680","volume":"339","author":"SA Greenberg","year":"2009","unstructured":"Greenberg, S. A. How citation distortions create unfounded authority: analysis of a citation network. BMJ 339, b2680 (2009).","journal-title":"BMJ"},{"key":"186_CR204","doi-asserted-by":"publisher","first-page":"b2049","DOI":"10.1136\/bmj.b2049","volume":"339","author":"D Fergusson","year":"2009","unstructured":"Fergusson, D. Inappropriate referencing in research. BMJ 339, b2049 (2009).","journal-title":"BMJ"},{"key":"186_CR205","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1006\/exnr.1994.1109","volume":"128","author":"E Sarkozi","year":"1994","unstructured":"Sarkozi, E., Askanas, V., Johnson, S. A., McFerrin, J. & Engel, W. K. Expression of \u03b2-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp. Neurol. 128, 27\u201333 (1994).","journal-title":"Exp. Neurol."},{"key":"186_CR206","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.lpm.2010.11.024","volume":"40","author":"V Askanas","year":"2011","unstructured":"Askanas, V. & Engel, W. K. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-\u03b242 oligomers and phosphorylated tau. Presse Med. 40, e219\u2013e235 (2011).","journal-title":"Presse Med."},{"key":"186_CR207","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/mus.21471","volume":"40","author":"M Salajegheh","year":"2009","unstructured":"Salajegheh, M. et al. Nature of \u201cTau\u201d immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 40, 520\u2013528 (2009).","journal-title":"Muscle Nerve"},{"key":"186_CR208","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.410390122","volume":"39","author":"JN Pruitt 2nd","year":"1996","unstructured":"Pruitt, J. N. 2nd, Showalter, C. J. & Engel, A. G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39, 139\u2013143 (1996).","journal-title":"Ann. Neurol."},{"key":"186_CR209","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/WNL.54.5.1033","volume":"54","author":"BL Banwell","year":"2000","unstructured":"Banwell, B. L. & Engel, A. G. \u03b1B-Crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54, 1033\u20131041 (2000).","journal-title":"Neurology"},{"key":"186_CR210","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0304-3940(95)11718-C","volume":"194","author":"FE Sherriff","year":"1995","unstructured":"Sherriff, F. E., Joachim, C. L., Squier, M. V. & Esiri, M. M. Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not \u03b2-amyloid. Neurosci. Lett. 194, 37\u201340 (1995).","journal-title":"Neurosci. Lett."},{"key":"186_CR211","first-page":"103","volume":"30","author":"O Dubourg","year":"2011","unstructured":"Dubourg, O. et al. Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 30, 103\u2013108 (2011).","journal-title":"Acta Myol"},{"key":"186_CR212","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2051-5960-1-29","volume":"1","author":"A Hiniker","year":"2013","unstructured":"Hiniker, A., Daniels, B. H., Lee, H. S. & Margeta, M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol. Commun. 1, 29 (2013).","journal-title":"Acta Neuropathol. Commun."},{"key":"186_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0002-9440(10)63089-1","volume":"164","author":"G Vattemi","year":"2004","unstructured":"Vattemi, G., Engel, W. K., McFerrin, J. & Askanas, V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am. J. Pathol. 164, 1\u20137 (2004).","journal-title":"Am. J. Pathol."},{"key":"186_CR214","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ana.21115","volume":"61","author":"JD Lunemann","year":"2007","unstructured":"Lunemann, J. D. et al. \u03b2-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann. Neurol. 61, 476\u2013483 (2007).","journal-title":"Ann. Neurol."},{"key":"186_CR215","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.nmd.2016.12.009","volume":"27","author":"S Nakano","year":"2017","unstructured":"Nakano, S., Oki, M. & Kusaka, H. The role of p62\/SQSTM1 in sporadic inclusion body myositis. Neuromuscul. Disord. 27, 363\u2013369 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR216","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.nmd.2014.04.012","volume":"24","author":"JL Pinkus","year":"2014","unstructured":"Pinkus, J. L., Amato, A. A., Taylor, J. P. & Greenberg, S. A. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul. Disord. 24, 611\u2013616 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR217","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp.2007.131334","volume":"79","author":"CC Weihl","year":"2008","unstructured":"Weihl, C. C. et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 79, 1186\u20131189 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"186_CR218","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mus.21386","volume":"40","author":"M Salajegheh","year":"2009","unstructured":"Salajegheh, M. et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40, 19\u201331 (2009).","journal-title":"Muscle Nerve"},{"key":"186_CR219","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00401-009-0564-6","volume":"118","author":"A Nogalska","year":"2009","unstructured":"Nogalska, A., Terracciano, C., D\u2019Agostino, C., King Engel, W. & Askanas, V. p62\/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol. 118, 407\u2013413 (2009).","journal-title":"Acta Neuropathol."},{"key":"186_CR220","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1136\/bmj.329.7480.1464","volume":"329","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman, G. J. & van Engelen, B. G. Polymyositis invasion of non-necrotic muscle fibres, and the art of repetition. BMJ 329, 1464\u20131467 (2004).","journal-title":"BMJ"},{"key":"186_CR221","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12675","volume":"17","author":"LA Callender","year":"2018","unstructured":"Callender, L. A. et al. Human CD8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell 17, e12675 (2018).","journal-title":"Aging Cell"},{"key":"186_CR222","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/eji.200737687","volume":"38","author":"LK Chong","year":"2008","unstructured":"Chong, L. K. et al. Proliferation and interleukin 5 production by CD8hi CD57+ T cells. Eur. J. Immunol. 38, 995\u20131000 (2008).","journal-title":"Eur. J. Immunol."},{"key":"186_CR223","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11357-009-9100-9","volume":"31","author":"SM Henson","year":"2009","unstructured":"Henson, S. M. & Akbar, A. N. KLRG1\u2014more than a marker for T cell senescence. Age 31, 285\u2013291 (2009).","journal-title":"Age"},{"key":"186_CR224","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri2959","volume":"11","author":"AN Akbar","year":"2011","unstructured":"Akbar, A. N. & Henson, S. M. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat. Rev. Immunol. 11, 289\u2013295 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"186_CR225","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1136\/annrheumdis-2013-203881","volume":"73","author":"L Melis","year":"2014","unstructured":"Melis, L., Van Praet, L., Pircher, H., Venken, K. & Elewaut, D. Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-\u03b1 production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. Ann. Rheum. Dis. 73, 1223\u20131231 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"186_CR226","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/imm.12506","volume":"146","author":"IE Dumitriu","year":"2015","unstructured":"Dumitriu, I. E. The life (and death) of CD4+CD28null T cells in inflammatory diseases. Immunology 146, 185\u2013193 (2015).","journal-title":"Immunology"},{"key":"186_CR227","first-page":"348746","volume":"2015","author":"K Maly","year":"2015","unstructured":"Maly, K. & Schirmer, M. The story of CD4+CD28- T cells revisited: solved or still ongoing? J. Immunol. Res. 2015, 348746 (2015).","journal-title":"J. Immunol. Res."},{"key":"186_CR228","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/bjd.13993","volume":"173","author":"XT Lima","year":"2015","unstructured":"Lima, X. T. et al. Frequency and characteristics of circulating CD4+ CD28null T cells in patients with psoriasis. Br. J. Dermatol. 173, 998\u20131005 (2015).","journal-title":"Br. J. Dermatol."},{"key":"186_CR229","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4049\/jimmunol.161.2.1018","volume":"161","author":"M Schirmer","year":"1998","unstructured":"Schirmer, M., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J. Immunol. 161, 1018\u20131025 (1998).","journal-title":"J. Immunol."},{"key":"186_CR230","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/ar386","volume":"4","author":"M Schirmer","year":"2002","unstructured":"Schirmer, M. et al. Circulating cytotoxic CD8+ CD28- T cells in ankylosing spondylitis. Arthritis Res. 4, 71\u201376 (2002).","journal-title":"Arthritis Res."},{"key":"186_CR231","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.04.003","volume":"147","author":"E Liaskou","year":"2014","unstructured":"Liaskou, E. et al. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 147, 221\u2013232 (2014).","journal-title":"Gastroenterology"},{"key":"186_CR232","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","volume":"72","author":"C Dejaco","year":"2013","unstructured":"Dejaco, C. et al. NKG2D stimulated T cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 72, 1852\u20131859 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"186_CR233","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00296-009-0949-9","volume":"30","author":"C Dejaco","year":"2010","unstructured":"Dejaco, C., Duftner, C., Klauser, A. & Schirmer, M. Altered T cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica. Rheumatol. Int. 30, 297\u2013303 (2010).","journal-title":"Rheumatol. Int."},{"key":"186_CR234","doi-asserted-by":"publisher","first-page":"R292","DOI":"10.1186\/ar793","volume":"5","author":"C Duftner","year":"2003","unstructured":"Duftner, C. et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res. Ther. 5, R292\u2013R300 (2003).","journal-title":"Arthritis Res. Ther."},{"key":"186_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.11.008","volume":"243","author":"MJ Pinto-Medel","year":"2012","unstructured":"Pinto-Medel, M. J. et al. The CD4+T cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis. J. Neuroimmunol. 243, 1\u201311 (2012).","journal-title":"J. Neuroimmunol."},{"key":"186_CR236","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/B:JOCI.0000019784.20191.7f","volume":"24","author":"J Garcia de Tena","year":"2004","unstructured":"Garcia de Tena, J. et al. Active Crohn\u2019s disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J. Clin. Immunol. 24, 185\u2013196 (2004).","journal-title":"J. Clin. Immunol."},{"key":"186_CR237","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/fon.12.75","volume":"8","author":"F Leblanc","year":"2012","unstructured":"Leblanc, F., Zhang, D., Liu, X. & Loughran, T. P. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 8, 787\u2013801 (2012).","journal-title":"Future Oncol."},{"key":"186_CR238","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.nmd.2013.09.008","volume":"23","author":"FL Mastaglia","year":"2013","unstructured":"Mastaglia, F. L. et al. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul. Disord. 23, 969\u2013974 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"186_CR239","doi-asserted-by":"publisher","first-page":"1766.e1","DOI":"10.1016\/j.neurobiolaging.2014.12.039","volume":"36","author":"Q Gang","year":"2015","unstructured":"Gang, Q. et al. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol. Aging 36, 1766.e1\u20131766.e3 (2015).","journal-title":"Neurobiol. Aging"},{"key":"186_CR240","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neulet.2012.11.064","volume":"535","author":"B Paepe De","year":"2013","unstructured":"De Paepe, B. & De Bleecker, J. L. The nonnecrotic invaded muscle fibers of polymyositis and sporadic inclusion body myositis: on the interplay of chemokines and stress proteins. Neurosci. Lett. 535, 18\u201323 (2013).","journal-title":"Neurosci. Lett."},{"key":"186_CR241","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.2741\/2866","volume":"13","author":"B Paepe De","year":"2008","unstructured":"De Paepe, B., Creus, K. K. & De Bleecker, J. L. Chemokines in idiopathic inflammatory myopathies. Front. Biosci. 13, 2548\u20132577 (2008).","journal-title":"Front. Biosci."},{"key":"186_CR242","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","volume":"179","author":"J Ivanidze","year":"2011","unstructured":"Ivanidze, J. et al. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-\u03b3 signaling cascade in attacked versus nonattacked myofibers. Am. J. Pathol. 179, 1347\u20131359 (2011).","journal-title":"Am. J. Pathol."},{"key":"186_CR243","first-page":"1852","volume":"22","author":"AL Mammen","year":"2016","unstructured":"Mammen, A. L. Autoimmune myopathies. Continuum 22, 1852\u20131870 (2016).","journal-title":"Continuum"},{"key":"186_CR244","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","volume":"7","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat. Rev. Neurol. 7, 343\u2013354 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"186_CR245","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/BOR.0000000000000441","volume":"29","author":"AL Mammen","year":"2017","unstructured":"Mammen, A. L. Which nonautoimmune myopathies are most frequently misdiagnosed as myositis? Curr. Opin. Rheumatol. 29, 618\u2013622 (2017).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR246","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-018-0738-0","volume":"20","author":"KA Britson","year":"2018","unstructured":"Britson, K. A., Yang, S. Y. & Lloyd, T. E. New developments in the genetics of inclusion body myositis. Curr. Rheumatol. Rep. 20, 26 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"186_CR247","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2990.2007.00864.x","volume":"34","author":"M Olive","year":"2008","unstructured":"Olive, M. et al. Expression of mutant ubiquitin (UBB+1) and p62 in myotilinopathies and desminopathies. Neuropathol. Appl. Neurobiol. 34, 76\u201387 (2008).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"186_CR248","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/NEN.0b013e3181996d8f","volume":"68","author":"M Olive","year":"2009","unstructured":"Olive, M. et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J. Neuropathol. Exp. Neurol. 68, 262\u2013273 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"186_CR249","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40478-016-0384-6","volume":"4","author":"S Duleh","year":"2016","unstructured":"Duleh, S., Wang, X., Komirenko, A. & Margeta, M. Activation of the Keap1\/Nrf2 stress response pathway in autophagic vacuolar myopathies. Acta Neuropathol. Commun. 4, 115 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"186_CR250","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1002\/mus.880181312","volume":"2","author":"K Arahata","year":"1995","unstructured":"Arahata, K. et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl. 2, S56\u2013S66 (1995).","journal-title":"Muscle Nerve Suppl."},{"key":"186_CR251","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1212\/WNL.57.11.2136","volume":"57","author":"E Gallardo","year":"2001","unstructured":"Gallardo, E. et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57, 2136\u20132138 (2001).","journal-title":"Neurology"},{"key":"186_CR252","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JND-160153","volume":"3","author":"P Castets","year":"2016","unstructured":"Castets, P., Frank, S., Sinnreich, M. & Ruegg, M. A. \u201cGet the balance right\u201d: pathological significance of autophagy perturbation in neuromuscular disorders. J. Neuromuscul. Dis. 3, 127\u2013155 (2016).","journal-title":"J. Neuromuscul. Dis."},{"key":"186_CR253","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/BOR.0b013e32833f108a","volume":"22","author":"AS Varadhachary","year":"2010","unstructured":"Varadhachary, A. S., Weihl, C. C. & Pestronk, A. Mitochondrial pathology in immune and inflammatory myopathies. Curr. Opin. Rheumatol. 22, 651\u2013657 (2010).","journal-title":"Curr. Opin. Rheumatol."},{"key":"186_CR254","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","volume":"134","author":"A Meyer","year":"2017","unstructured":"Meyer, A. et al. IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol. 134, 655\u2013666 (2017).","journal-title":"Acta Neuropathol."},{"key":"186_CR255","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cell.2013.01.037","volume":"152","author":"JA Nathan","year":"2013","unstructured":"Nathan, J. A. et al. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152, 1184\u20131194 (2013).","journal-title":"Cell"},{"key":"186_CR256","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","volume":"142","author":"U Seifert","year":"2010","unstructured":"Seifert, U. et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142, 613\u2013624 (2010).","journal-title":"Cell"},{"key":"186_CR257","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.21103","volume":"52","author":"K Nagaraju","year":"2005","unstructured":"Nagaraju, K. et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52, 1824\u20131835 (2005).","journal-title":"Arthritis Rheum."},{"key":"186_CR258","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140248","volume":"10","author":"AS Correia","year":"2015","unstructured":"Correia, A. S., Patel, P., Dutta, K. & Julien, J. P. Inflammation induces TDP-43 mislocalization and aggregation. PLOS ONE 10, e0140248 (2015).","journal-title":"PLOS ONE"},{"key":"186_CR259","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2015.12.057","volume":"164","author":"Z Zhong","year":"2016","unstructured":"Zhong, Z. et al. NF-\u03baB restricts inflammasome activation via elimination of damaged mitochondria. Cell 164, 896\u2013910 (2016).","journal-title":"Cell"},{"key":"186_CR260","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1128\/JVI.78.19.10320-10327.2004","volume":"78","author":"S Ozden","year":"2004","unstructured":"Ozden, S. et al. Direct evidence for a chronic CD8+-T cell-mediated immune reaction to tax within the muscle of a human T cell leukemia\/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J. Virol. 78, 10320\u201310327 (2004).","journal-title":"J. Virol."},{"key":"186_CR261","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","volume":"193","author":"DR Green","year":"2003","unstructured":"Green, D. R., Droin, N. & Pinkoski, M. Activation-induced cell death in T cells. Immunol. Rev. 193, 70\u201381 (2003).","journal-title":"Immunol. Rev."},{"key":"186_CR262","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.4049\/jimmunol.165.11.6301","volume":"165","author":"AN Vallejo","year":"2000","unstructured":"Vallejo, A. N., Schirmer, M., Weyand, C. M. & Goronzy, J. J. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J. Immunol. 165, 6301\u20136307 (2000).","journal-title":"J. Immunol."},{"key":"186_CR263","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0531-5565(99)00033-9","volume":"34","author":"C Spaulding","year":"1999","unstructured":"Spaulding, C., Guo, W. & Effros, R. B. Resistance to apoptosis in human CD8+T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp. Gerontol. 34, 633\u2013644 (1999).","journal-title":"Exp. Gerontol."},{"key":"186_CR264","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/intimm\/11.2.229","volume":"11","author":"DN Posnett","year":"1999","unstructured":"Posnett, D. N., Edinger, J. W., Manavalan, J. S., Irwin, C. & Marodon, G. Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+CD28- cytotoxic effector clones. Int. Immunol. 11, 229\u2013241 (1999).","journal-title":"Int. Immunol."},{"key":"186_CR265","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fimmu.2016.00617","volume":"7","author":"G Hodge","year":"2016","unstructured":"Hodge, G. & Hodge, S. Steroid resistant CD8+CD28null NKT-like pro-inflammatory cytotoxic cells in chronic obstructive pulmonary disease. Front. Immunol. 7, 617 (2016).","journal-title":"Front. Immunol."},{"key":"186_CR266","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-016-0974-5","volume":"18","author":"JM Pandya","year":"2016","unstructured":"Pandya, J. M. et al. Effects of conventional immunosuppressive treatment on CD244+(CD28null) and FOXP3+T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res. Ther. 18, 80 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"186_CR267","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","volume":"5","author":"JP Pearl","year":"2005","unstructured":"Pearl, J. P. et al. Immunocompetent T cells with a memory-like phenotype are the dominant cell type following antibody-mediated T cell depletion. Am. J. Transplant. 5, 465\u2013474 (2005).","journal-title":"Am. J. Transplant."},{"key":"186_CR268","doi-asserted-by":"publisher","DOI":"10.1038\/srep23002","volume":"6","author":"MJ Olnes","year":"2016","unstructured":"Olnes, M. J. et al. Effects of systemically administered hydrocortisone on the human immunome. Sci. Rep. 6, 23002 (2016).","journal-title":"Sci. Rep."},{"key":"186_CR269","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"186_CR270","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2007-11-121871","volume":"112","author":"MV Shah","year":"2008","unstructured":"Shah, M. V. et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 112, 770\u2013781 (2008).","journal-title":"Blood"},{"key":"186_CR271","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","volume":"95","author":"B Bareau","year":"2010","unstructured":"Bareau, B. et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 95, 1534\u20131541 (2010).","journal-title":"Haematologica"},{"key":"186_CR272","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","volume":"3","author":"B Dumitriu","year":"2016","unstructured":"Dumitriu, B. et al. Alemtuzumab in T cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol. 3, e22\u2013e29 (2016).","journal-title":"Lancet Haematol."},{"key":"186_CR273","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3324\/haematol.2009.009191","volume":"94","author":"SR Mohan","year":"2009","unstructured":"Mohan, S. R. et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+large granular lymphocyte leukemia. Haematologica 94, 1407\u20131414 (2009).","journal-title":"Haematologica"},{"key":"186_CR274","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","volume":"59","author":"SE Gitelman","year":"2016","unstructured":"Gitelman, S. E. et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia 59, 1153\u20131161 (2016).","journal-title":"Diabetologia"},{"key":"186_CR275","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1432-2277.2010.01052.x","volume":"23","author":"M Scarsi","year":"2010","unstructured":"Scarsi, M. et al. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients. Transpl. Int. 23, 786\u2013795 (2010).","journal-title":"Transpl. Int."},{"key":"186_CR276","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.4049\/jimmunol.176.8.4632","volume":"176","author":"DC Neujahr","year":"2006","unstructured":"Neujahr, D. C. et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J. Immunol. 176, 4632\u20134639 (2006).","journal-title":"J. Immunol."},{"key":"186_CR277","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/ajt.13092","volume":"15","author":"T Crepin","year":"2015","unstructured":"Crepin, T. et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am. J. Transplant. 15, 1028\u20131038 (2015).","journal-title":"Am. J. Transplant."},{"key":"186_CR278","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/TP.0b013e318247a717","volume":"93","author":"C Macedo","year":"2012","unstructured":"Macedo, C. et al. Long-term effects of alemtuzumab on regulatory and memory T cell subsets in kidney transplantation. Transplantation 93, 813\u2013821 (2012).","journal-title":"Transplantation"},{"key":"186_CR279","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/rheumatology\/kem078","volume":"46","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M. & Brito-Zeron, P. Emerging biological therapies in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 46, 1389\u20131396 (2007).","journal-title":"Rheumatology"},{"key":"186_CR280","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","volume":"104","author":"M Lombard","year":"1993","unstructured":"Lombard, M. et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104, 519\u2013526 (1993).","journal-title":"Gastroenterology"},{"key":"186_CR281","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/hep.1840100405","volume":"10","author":"HC Mitchison","year":"1989","unstructured":"Mitchison, H. C. et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 10, 420\u2013429 (1989).","journal-title":"Hepatology"},{"key":"186_CR282","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","volume":"322","author":"RH Wiesner","year":"1990","unstructured":"Wiesner, R. H. et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 322, 1419\u20131424 (1990).","journal-title":"N. Engl. J. Med."},{"key":"186_CR283","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.4049\/jimmunol.163.4.2226","volume":"163","author":"T Fujihara","year":"1999","unstructured":"Fujihara, T. et al. Preferential localization of CD8+\u03b1E\u03b27 +T cells around acinar epithelial cells with apoptosis in patients with Sj\u00f6gren\u2019s syndrome. J. Immunol. 163, 2226\u20132235 (1999).","journal-title":"J. Immunol."},{"issue":"Suppl. 3","key":"186_CR284","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1872-034X.2007.00238.x","volume":"37","author":"H Kita","year":"2007","unstructured":"Kita, H. Autoreactive CD8-specific T cell response in primary biliary cirrhosis. Hepatol. Res. 37 (Suppl. 3), 402\u2013405 (2007).","journal-title":"Hepatol. Res."},{"key":"186_CR285","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/BF00915293","volume":"4","author":"L Si","year":"1984","unstructured":"Si, L., Whiteside, T. L., Schade, R. R., Starzl, T. E. & Van Thiel, D. H. T-Lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls. J. Clin. Immunol. 4, 262\u2013272 (1984).","journal-title":"J. Clin. Immunol."},{"key":"186_CR286","first-page":"1106","volume":"13","author":"A Bjorkland","year":"1991","unstructured":"Bjorkland, A. et al. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells. Hepatology 13, 1106\u20131111 (1991).","journal-title":"Hepatology"},{"key":"186_CR287","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1136\/annrheumdis-2016-210788","volume":"76","author":"S Tasaki","year":"2017","unstructured":"Tasaki, S. et al. Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 76, 1458\u20131466 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"186_CR288","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.24526","volume":"54","author":"M Tsuda","year":"2011","unstructured":"Tsuda, M. et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology 54, 1293\u20131302 (2011).","journal-title":"Hepatology"},{"key":"186_CR289","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00109-015-1297-8","volume":"93","author":"Z Yang","year":"2015","unstructured":"Yang, Z., Goronzy, J. J. & Weyand, C. M. Autophagy in autoimmune disease. J. Mol. Med. 93, 707\u2013717 (2015).","journal-title":"J. Mol. Med."},{"key":"186_CR290","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/MOG.0000000000000144","volume":"31","author":"S Hosomi","year":"2015","unstructured":"Hosomi, S., Kaser, A. & Blumberg, R. S. Role of endoplasmic reticulum stress and autophagy as interlinking pathways in the pathogenesis of inflammatory bowel disease. Curr. Opin. Gastroenterol. 31, 81\u201388 (2015).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"186_CR291","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2016.62","volume":"16","author":"J Grootjans","year":"2016","unstructured":"Grootjans, J., Kaser, A., Kaufman, R. J. & Blumberg, R. S. The unfolded protein response in immunity and inflammation. Nat. Rev. Immunol. 16, 469\u2013484 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"186_CR292","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1478-3231.2011.02656.x","volume":"32","author":"M Sasaki","year":"2012","unstructured":"Sasaki, M., Miyakoshi, M., Sato, Y. & Nakanuma, Y. A possible involvement of p62\/sequestosome-1 in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis. Liver Int. 32, 487\u2013499 (2012).","journal-title":"Liver Int."},{"key":"186_CR293","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/labinvest.2010.56","volume":"90","author":"M Sasaki","year":"2010","unstructured":"Sasaki, M., Miyakoshi, M., Sato, Y. & Nakanuma, Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. Lab. Invest. 90, 835\u2013843 (2010).","journal-title":"Lab. Invest."},{"key":"186_CR294","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00535-014-1033-0","volume":"50","author":"M Sasaki","year":"2015","unstructured":"Sasaki, M., Yoshimura-Miyakoshi, M., Sato, Y. & Nakanuma, Y. A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. J. Gastroenterol. 50, 984\u2013995 (2015).","journal-title":"J. Gastroenterol."},{"key":"186_CR295","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/cei.12638","volume":"181","author":"S Katsiougiannis","year":"2015","unstructured":"Katsiougiannis, S., Tenta, R. & Skopouli, F. N. Endoplasmic reticulum stress causes autophagy and apoptosis leading to cellular redistribution of the autoantigens Ro\/Sj\u00f6gren\u2019s syndrome-related antigen A (SSA) and La\/SSB in salivary gland epithelial cells. Clin. Exp. Immunol. 181, 244\u2013252 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"186_CR296","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","volume":"72","author":"RL Leff","year":"1993","unstructured":"Leff, R. L., Miller, F. W., Hicks, J., Fraser, D. D. & Plotz, P. H. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 72, 225\u2013235 (1993).","journal-title":"Medicine"},{"key":"186_CR297","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1212\/WNL.43.5.876","volume":"43","author":"SA Soueidan","year":"1993","unstructured":"Soueidan, S. A. & Dalakas, M. C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43, 876\u2013879 (1993).","journal-title":"Neurology"},{"key":"186_CR298","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","volume":"44","author":"AA Amato","year":"1994","unstructured":"Amato, A. A. et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 44, 1516\u20131518 (1994).","journal-title":"Neurology"},{"key":"186_CR299","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","volume":"45","author":"RJ Barohn","year":"1995","unstructured":"Barohn, R. J., Amato, A. A., Sahenk, Z., Kissel, J. T. & Mendell, J. R. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 45, 1302\u20131304 (1995).","journal-title":"Neurology"},{"key":"186_CR300","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","volume":"66","author":"RJ Barohn","year":"2006","unstructured":"Barohn, R. J. et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66, S123\u2013S124 (2006).","journal-title":"Neurology"},{"key":"186_CR301","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","volume":"334","author":"ML Kosmidis","year":"2013","unstructured":"Kosmidis, M. L., Alexopoulos, H., Tzioufas, A. G. & Dalakas, M. C. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J. Neurol. Sci. 334, 123\u2013125 (2013).","journal-title":"J. Neurol. Sci."},{"key":"186_CR302","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00079768 (2010)."},{"key":"186_CR303","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00917956 (2010)."},{"key":"186_CR304","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01519349 (2017)."},{"key":"186_CR305","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02483845 (2017)."},{"key":"186_CR306","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02250443 (2018)."},{"key":"186_CR307","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00802815 (2014)."},{"key":"186_CR308","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00769860 (2017)."},{"key":"186_CR309","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01423110 (2017)."},{"key":"186_CR310","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01925209 (2017)."},{"key":"186_CR311","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02481453 (2019)."},{"key":"186_CR312","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02753530 (2018)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0186-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T07:24:07Z","timestamp":1721028247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-019-0186-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":312,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1038\/s41584-019-0186-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"5 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.G. is an inventor of intellectual property related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women\u2019s Hospital; he receives sponsored research from Pfizer, Inc. and is a founder of Abcuro, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}